Hormonal
The ER22/23EK polymorphism in the glucocorticoid receptor gene confers relative resistance to glucocorticoids, resulting in a healthier metabolic profile characterized by lower fasting insulin, increased insulin sensitivity, and lower cholesterol levels.
If you carry the ER22/23EK variant, your body naturally handles glucocorticoids differently, leading to better insulin sensitivity and lower cholesterol. This is a protective genetic factor. Focus on maintaining this advantage through standard healthy living, as your biology already supports a favorable metabolic profile compared to non-carriers.
In line with this, ER22/23EK carriers had lower total cholesterol and low-density lipoprotein cholesterol levels as well as lower fasting insulin concentrations and a better insulin sensitivity.
Why this rating
Based on multiple large cohort studies (Rotterdam study) with consistent findings across different age groups and metabolic markers.
Source
Polymorphisms in the Glucocorticoid Receptor Gene and Their Associations with Metabolic Parameters and Body Composition
Elisabeth F. C. van Rossum · Recent Progress in Hormone Research · 2004
DOI 10.1210/rp.59.1.333
More from this paper
- The ER22/23EK polymorphism is associated with increased lean body mass and muscle strength in young adult males, and reduced abdominal fat measures in young adult females, due to relative glucocorticoid resistance.Good
- The ER22/23EK polymorphism is associated with a lower risk of dementia, fewer white matter lesions, and significantly better survival rates in the elderly.Good
- The N363S polymorphism is associated with increased glucocorticoid sensitivity, higher BMI, and increased insulin response to dexamethasone, though associations with BMI are controversial across different populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →